Rationale Kappa agonists can attenuate reinstatement of cocaine-seeking behavior induced by cocaine priming. The mechanisms underlying this effect have not been characterized fully but may have a serotonergic component as kappa agonists also increase the release of serotonin (5-hydroxytryptamine, 5-HT). Objectives This study investigated the role of kappa opioid receptor and 5-HT mechanisms in kappa agonist-induced attenuation of cocaine priming in monkeys. Methods Squirrel monkeys were trained to self-administer cocaine (0.18-0.3 mg/kg/injection) under a second-order schedule in which drug seeking was maintained jointly by cocaine injections and a cocaine-paired visual stimulus. In extinction sessions, saline was substituted for cocaine, and the cocaine-paired stimulus was omitted. During test sessions, only saline was available for self-administration, and response-contingent presentations of the cocaine-paired stimulus were restored. Results Priming injections of cocaine (0.1-1.0 mg/kg) induced reinstatement of drug seeking. Maximal levels of responding were similar to those maintained by active cocaine self-administration. Pretreatment with the kappa agonists enadoline (0.01 mg/kg) and spiradoline (0.3 mg/ kg) or the 5-HT transport inhibitors fluoxetine (5.6 mg/kg) and citalopram (10.0 mg/kg) attenuated the priming effects of cocaine, shifting the cocaine dose-response function rightward and downward. Inhibition of cocaine-induced reinstatement of drug seeking by spiradoline and fluoxetine was reversed by R(+)8-hydroxy-2-(di-n-propylamino)tetralin (0.03 mg/kg), a 5HT 1A agonist that inhibits 5-HT release. The effects of spiradoline also were reversed by the kappa antagonist nor-binaltorphimine (10.0 mg/kg). Conclusions Results suggest that the capacity of kappa opioid agonists to increase extracellular 5-HT levels may at least partially underlie kappa agonist-induced modulation of cocaine seeking.
also have been found to reduce cocaine self-administration in rhesus monkeys and rats, an effect that could be reversed by the kappa opioid antagonist nor-binaltorphimine (nor-BNI; Glick et al. 1995; Negus et al. 1997; Mello and Negus 1998; Schenk et al. 1999 ). Lastly, in reinstatement studies in rats, the capacity of cocaine to reinstate extinguished drugseeking behavior was blunted by pretreatment with the kappa opioid agonist U69593 (Schenk et al. 1999) .
The mechanism underlying the capacity of kappa opioid agonists to attenuate the effects of cocaine is often presumed to be related to their capacity to inhibit dopamine (DA) neurotransmission, as kappa opioid agonists can inhibit DA release from the nucleus accumbens (Di Chiara and Imperato 1988; Spanagel et al. 1990 ; Thompson et al. 2000) , decrease striatal DA levels (Devine et al. 1993) , and inhibit firing of DA neurons (Walker et al. 1987) . However, results from in vitro and in vivo studies suggest that kappa opioid agonists also can modulate the serotonin (5-hydroxytryptamine, 5-HT) system. For example, application of U50,488H to both human and rat brain slices enhanced the outflow of electrically evoked and K + -evoked [ 3 H]5-HT (Ho and Takemori 1990; Berger et al. 2006) . In vivo, i.c.v. administration of U50,488H produced analgesia and induced supraspinal release of 5-HT in mice (Ho and Takemori 1989) . Moreover, kappa opioid agonist-induced analgesia was attenuated by 5-HT depletion with pchlorophenylalanine as well as by several 5-HT antagonists (Von Voigtlander et al. 1984; Ho and Takemori 1989) . In drug discrimination studies in pigeons and rats, the discriminative stimulus effects of U50,488H were attenuated following 5-HT depletion as well as after pretreatment with several 5-HT ligands including the 5-HT 1A receptor agonist R(+)8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), the 5-HT 2 receptor antagonist ketanserin, and the 5-HT 3 receptor antagonist MDL72222-all of which inhibit serotonergic activity (Bronson et al. 1993; Powell et al. 1994) . Lastly, the kappa opioid agonist U69593 attenuated drug seeking induced by priming injections of cocaine and RTI-55 (a cocaine analog with greater affinity for the 5-HT transporter compared to the DA transporter), but not drug seeking induced by the DA uptake inhibitor GBR 12909 or by WIN 35,428 (a cocaine analog with greater affinity for the DA transporter compared to the 5-HT transporter; Schenk et al. 2000) . Together, these findings support the idea that 5-HT release and the subsequent stimulation of 5-HT receptors may be an important mechanism underlying the neurochemical and behavioral effects of kappa opioid agonists.
The idea that kappa opioid agonists may attenuate the abuse-related effects of cocaine via 5-HT mechanisms is supported by evidence of a general inhibitory role for 5-HT in modulating the behavioral effects of cocaine, especially in nonhuman primates. For example, in squirrel monkeys, 5-HT transport inhibitors attenuated the discriminative stimulus effects of cocaine in some cases (Spealman 1993 , but see Schama et al. 1997) and reduced the reinforcing effects of cocaine (Howell and Byrd 1995; Czoty et al. 2002) . In vivo microdialysis studies in monkeys have shown that 5-HT transport inhibitors also lessened cocaine-induced increase of extracellular DA in the caudate nucleus (Czoty et al. 2002) .
The purpose of the present study was to investigate the capacity of kappa opioid agonists to attenuate cocaine priming-induced reinstatement of drug-seeking behavior in squirrel monkeys. Because these agonists can have effects that are mediated by nonopioid receptor mechanisms, we directly evaluated the role of kappa opioid receptors in their cocaine-attenuating effects with the kappa opioid receptor antagonist nor-BNI. To evaluate the potential role of 5-HT mechanisms in the cocaineblunting effects of kappa opioid agonists, attenuation of reinstatement by the kappa opioid agonists was compared directly with attenuation induced by representative 5-HT transport inhibitors. Finally, to assess the involvement of 5-HT 1A receptor mechanisms in the cocaine-antagonizing effects of both kappa opioid agonists and 5-HT transport inhibitors, the capacity of the 5-HT 1A -agonist 8-OH-DPAT to reverse the effects of spiradoline and fluoxetine was determined.
Materials and methods
Subjects Adult squirrel monkeys (Saimiri sciureus) weighing 0.7-1.0 kg were housed individually in a climatecontrolled vivarium, where they had access to water ad libitum and received a nutritionally balanced diet of monkey chow (Teklad monkey diet) supplemented with fresh fruit. A total of seven monkeys were studied, with groups of at least four monkeys serving as subjects in each experiment (see below). Monkeys used in these studies had participated in an earlier study looking at the contribution of DA and noradrenergic mechanisms to cocaine-induced reinstatement (cf. Platt et al. 2007 Platt et al. (2005) . Briefly, monkeys were anesthetized with isoflurane, and one end of the catheter was passed by way of either a jugular or femoral vein to the level of the right atrium. The distal end of the catheter was passed subcutaneously and exited in the midscapular region. Catheters were flushed daily with 0.9% saline solution and were sealed with stainless steel obturators when not in use. Monkeys wore nylon-mesh jackets (Lomir Biomedical, Toronto, Canada) at all times to protect the catheter.
Apparatus Experimental sessions were conducted in ventilated sound-attenuating chambers which were provided with white noise to mask external sounds. Within the chamber, monkeys were seated in a Plexiglas chair facing a panel that was equipped with a response lever and colored stimulus lights above the lever (Med Associates, Inc., Georgia, VT, USA). Catheters were connected to syringe pumps (Med Associates, Inc., Georgia, VT, USA) located outside the chamber. Each operation of the pump delivered a 1-s infusion of 0.18 ml of vehicle or drug solution into the catheter.
Second-order schedule of cocaine injection Monkeys were trained to self-administer cocaine under a second-order fixed interval (FI), fixed ratio (FR) schedule of i.v. drug injection similar to the schedule described by Khroyan et al. (2000) . Briefly, in the presence of a white light, completion of every tenth or 30th response (FR10 or FR30, depending on the particular monkey) during a 10-min FI resulted in a 2-s change in illumination from white to red. Completion of the first FR after expiration of the FI resulted in an i.v. injection of cocaine simultaneous with the onset of the red light (cocaine-paired stimulus (S)). A 60-s time-out (TO) period, during which all lights were off and responses had no scheduled consequences, followed each injection. If the FR requirement was not completed within 8 min following the expiration of the FI, the component ended automatically without an injection and was followed by a 60-s TO period. Daily sessions ended after completion of five cycles of the second-order schedule (maximum of 90 min). Initially, the dose of cocaine was varied over a 10-fold range (0.03-0.3 mg/kg/ injection) to determine the dose that maintained maximum rates of responding for each monkey. For six monkeys, 0.18 mg/kg/injection maintained maximum response rates, whereas for the remaining monkey, 0.3 mg/kg/injection maintained maximum response rates.
Extinction and reinstatement of cocaine seeking Following a 6-to 8-month period of stable cocaine self-administration, responding was extinguished by substituting saline for cocaine and omitting presentations of the cocaine-paired stimulus. Extinction sessions, including session and TO durations, were otherwise identical to those described above. Extinction sessions were conducted daily until responding declined and stabilized at ≤10% of the response rate maintained by cocaine self-administration (three to ten sessions depending on the subject).
Following extinction, a range of doses of noncontingent priming injections of cocaine (0.1-1.0 mg/kg), as well as saline vehicle, were assessed for their capacity to reinstate drug-seeking behavior during test sessions in which only saline was available for self-administration. Responsecontingent presentations of the cocaine-paired stimulus also were restored during these test sessions because earlier studies showed that reinstatement of cocaine-seeking behavior was the greatest when cocaine priming was accompanied by restoration of the cocaine-paired stimulus (Spealman et al. 2004) . Priming injections of cocaine were administered i.v. immediately before the session. Different doses of cocaine were tested on different days, with each test session separated by one or more extinction sessions as described above. The order in which each priming dose of cocaine was tested varied across monkeys. After completion of these experiments, cocaine self-administration was reestablished using the procedures described previously until responding stabilized, and there were no systematic upward or downward trends in response rates over at least three consecutive sessions. This reestablishment of cocaine self-administration occurred at least monthly, after completion of one part of the study and before testing another set of drugs.
Effects of kappa opioid ligands on reinstatement of cocaine seeking Following completion of the test sequence with priming doses of cocaine, reestablishment of stable cocaine self-administration, and subsequent extinction of responding, the effects of kappa opioid agonists on cocaine-induced drug seeking were determined. The kappa opioid agonists used in this experiment included spiradoline (U62066) and enadoline (Cl 977 HCl). Agonists were given i.v. immediately prior to i.v. administration of cocaine priming doses (range 0.1-1.0 mg/kg). Spiradoline was tested at a dose of 0.3 mg/kg and enadoline at a dose of 0.01 mg/kg. These doses were found to be maximally effective at reinstating cocaine-seeking behavior when tested alone in an earlier study with squirrel monkeys (Valdez et al. 2007 ) and did not consistently reduce rates of responding in other procedures in squirrel monkeys (e.g., drug discrimination: Carey and Bergman 2001; FI stimulus-shock termination: Powell and Holtzman 1999; shock titration: Pitts and Dykstra 1994, Powell and Dykstra 1995) . At the end of experiments with each kappa opioid agonist, the priming effect of 1.0 mg/kg cocaine was reevaluated to assess potential shifts in baseline levels of responding.
Subsequently, an antagonism study was conducted with the kappa opioid antagonist nor-BNI. Nor-BNI (10.0 mg/kg, i.m.) was administered at least 1 day before i.v. priming with cocaine alone or spiradoline plus cocaine. These parameters were selected on the basis of a previous study showing that nor-BNI exhibits selective kappa opioid receptor antagonist effects beginning 1 day after administration and lasting at least 25 days in squirrel monkeys (Carey and Bergman 2001) . As in reinstatement tests described above, only saline was available for self-administration, and responsecontingent presentations of the cocaine-paired stimulus were restored during the test.
Effects of serotonergic ligands on reinstatement of cocaine seeking After completion of experiments involving kappa opioid ligands and a 1-week washout period, the effects of the 5-HT transport inhibitors fluoxetine and citalopram on extinguished drug seeking were determined using the testing procedures described above. Initially, fluoxetine (0.3-5.6 mg/kg, i.v.) or citalopram (0.3-10.0 mg/kg, i.v.) was administered alone immediately prior to the test session. Dose ranges for each drug were selected on the basis of earlier studies in squirrel monkeys (Spealman 1993; Howell and Byrd 1995) . To evaluate the effects of the 5-HT transport inhibitors on cocaine-seeking behavior, the highest doses of fluoxetine (5.6 mg/kg) and citalopram (10.0 mg/kg) were administered in combination with a range of cocaine priming doses (0.1-1.0 mg/kg). Importantly, these doses of the 5-HT transport inhibitors do not consistently alter rates of responding in squirrel monkeys in other procedures (e.g., drug discrimination: Spealman 1993 , Schama et al. 1997 ; FI stimulus-shock termination: Spealman 1993, Howell and Byrd 1995) . At the end of experiments with each 5-HT transport inhibitor, the priming effect of 1.0 mg/kg cocaine was reevaluated to assess potential shifts in baseline levels of responding.
In order to assess the involvement of 5-HT release in the attenuation of cocaine seeking by kappa agonists and 5-HT transport inhibitors, 0.03 mg/kg of 8-OH-DPAT, a 5-HT 1A agonist, was administered i.m. 10 min prior to the infusion of spiradoline (0.3 mg/kg) or fluoxetine (5.6 mg/kg) combined with the maximally effective dose of cocaine (1.0 mg/kg). The dose and pretreatment interval for 8-OH-DPAT was based on an earlier study by Bronson et al. (1993) . We also determined the capacity of 8-OH-DPAT (0.003-0.1 mg/kg) to reinstate cocaine-seeking behavior in the absence of cocaine priming and to alter the effects of cocaine priming in the absence of either spiradoline or fluoxetine. As in reinstatement testing with cocaine alone, only saline was available for self-administration, and response-contingent presentations of the cocaine-paired stimulus were restored.
Data analysis The rate of responding in individual monkeys was computed for each session by dividing the total number of responses by the total elapsed time (excluding responses and time during TO periods). For each experimental condition, the mean response rate±standard error of the mean (SEM) was calculated for groups of four to seven monkeys. Statistical analysis was conducted using SigmaStat 3.0. Data were analyzed by one-way or two-way repeated measures analysis of variance and Bonferroni t tests, when appropriate, to assess differences between control conditions and test drugs. The control conditions were either vehicle priming tests for experiments in which the drugs were tested alone, or cocaine priming alone, for experiments in which cocaine was combined with other drugs.
Drugs Cocaine hydrochloride, enadoline hydrochloride, nor-BNI dihydrochloride, and citalopram hydrobromide were dissolved in 0.9% saline solution. Fluoxetine hydrochloride, 8-OH-DPAT hydrobromide, and spiradoline mesylate were dissolved in sterile water. Compounds were purchased from Tocris Cookson (Ellisville, MO, USA) and Sigma Aldrich (St. Louis, MO, USA).
Results
Cocaine self-administration, extinction, and priminginduced reinstatement In all monkeys, self-administered cocaine maintained high rates of responding under the second-order schedule of i.v. drug injection, ranging from 0.5 to 2.2 responses/s in individual monkeys (group mean 1.2±0.27 responses/s, n=7). During extinction sessions, in which only saline was available for self-administration and the cocaine-paired stimulus was omitted, responding declined and stabilized at low rates, ranging from 0 to 0.19 responses/s, depending on the individual monkey (group mean 0.045±0.015 responses/s). As depicted in Fig. 1 , priming injections of cocaine (0.1-1.0 mg/kg) prior to test sessions in which the cocaine-paired stimulus was restored but only saline was available for self-administration produced a dose-dependent reinstatement of extinguished cocaine-seeking behavior (F(3, 18)=18.03, p<0.001). Average response rates after administration of 0.3 and 1.0 mg/kg cocaine primes were significantly higher than rates obtained after administration of vehicle (p<0.001 each, Bonferroni t tests) and approached response rates maintained by active cocaine self-administration. Priming with a lower dose of cocaine (0.1 mg/kg) did not reinstate extinguished drug seeking above levels observed during extinction or following vehicle injections.
Effects of kappa opioid agonists on reinstatement of cocaine seeking Although both kappa agonists induced some cocaine-seeking behavior on their own (Fig. 2 , points above "alone"), they also attenuated cocaine-induced reinstatement, shifting the cocaine priming dose-response function downward (Fig. 2) . Pretreatment with 0.3 mg/kg of spiradoline before the two highest priming doses of cocaine significantly attenuated reinstatement (0.3 mg/kg cocaine: p<0.026; 1.0 mg/kg cocaine: p<0.002, Bonferroni t tests), as reflected by a significant spiradoline×cocaine prime interaction (F(2, 10)=12.04, p<0.002; Fig. 2 , white triangles). Similar to the findings with spiradoline, enadoline also blocked reinstatement induced by the two highest doses of cocaine (0.3 mg/kg cocaine: p<0.013; 1.0 mg/kg cocaine: p<0.004, Bonferroni t tests), as reflected by a significant enadoline×cocaine prime interaction (F(2, 10)= 8.82, p<0.006; Fig. 2, gray diamonds) .
Reversal of the effects of spiradoline by nor-BNI Compared to 1.0 mg/kg cocaine priming alone, pretreatment with 0.3 mg/kg spiradoline significantly reduced reinstatement of cocaine-seeking behavior (F(2, 6)=1.26, p<0.025; p<0.05, Bonferroni t test; Fig. 3a) . Pretreatment with 10.0 mg/kg nor-BNI at a minimum of 24 h before reinstatement testing reversed the effect of spiradoline on cocaine-induced reinstatement of drug seeking. As shown in Fig. 3 , the rate of responding returned to the level induced by cocaine priming alone. Pretreatment with 10.0 mg/kg nor-BNI before cocaine priming in the absence of spiradoline had no significant effect on the rate of responding (p>0.31; Fig. 3b ).
Effects of 5-HT transport inhibitors on reinstatement of cocaine seeking When various doses of fluoxetine or citalopram were given as primes at the beginning of a reinstatement session, there was no difference in rates of responding relative to a vehicle prime (fluoxetine: p>0.47; citalopram: p>0.60; Fig. 4a ). However, both 5-HT transport inhibitors attenuated cocaine-induced reinstatement of drug seeking, shifting the cocaine priming dose-response function downward (Fig. 4b) . Pretreatment with 5.6 mg/kg fluoxetine before cocaine priming significantly attenuated reinstatement of cocaine-seeking behavior compared to vehicle pretreatment (F(1, 10)=8.30, p<0.035; Fig. 4b , white triangles). There was a significant fluoxetine×cocaine prime interaction (F(2, 10)=6.71, p<0.014), reflecting the fact that there was no difference between vehicle and fluoxetine pretreatment administered before a 0.1-mg/kg cocaine prime (p>0.9, Bonferroni t test), but significant treatment differences with 0.3 (p<0.02, Bonferroni t test) and 1.0 mg/kg cocaine (p< 0.002, Bonferroni t test).
Similarly, when 10.0 mg/kg citalopram was given as a pretreatment before cocaine priming, there was a significant reduction in reinstatement of cocaine seeking relative to vehicle pretreatment (F(1, 6)=15.74, p<0.029; Fig. 4b , gray diamonds). As with fluoxetine pretreatment, citalopram attenuated reinstatement induced by 0.3 (p<0.006, Bonferroni t test) and 1.0 mg/kg cocaine (p<0.001, Bonferroni t test). This finding was supported by a significant citalopram×cocaine prime interaction (F(2, 10)=19.57, p<0.002).
Reversal of the effects of fluoxetine and spiradoline by 8-OH-DPAT Pretreatment with 0.3 mg/kg spiradoline before cocaine priming (1.0 mg/kg) significantly reduced reinstatement of drug seeking compared to cocaine priming in the absence of spiradoline (F(2, 6)=5.22, p<0.05; p<0.04, Bonferroni t test; Fig. 5a ). When 8-OH-DPAT (0.03 mg/kg) was administered as a pretreatment before the spiradolinecocaine combination, the attenuation of reinstatement was reversed (Bonferroni t test, p>0.36; Fig. 5a ). Similarly, when fluoxetine (5.6 mg/kg) was given as a pretreatment (Fig. 5c) .
Discussion
In the present study, pretreatment with the kappa opioid agonists spiradoline and enadoline significantly attenuated cocaine priming-induced reinstatement of drug seeking in squirrel monkeys previously trained to self-administer cocaine. The attenuation induced by the kappa opioid agonists appeared to be kappa opioid receptor mediated because the attenuation could be reversed with the kappa opioid antagonist nor-BNI. These results support and extend earlier studies in rats and nonhuman primates in which administration of kappa opioid agonists attenuated the discriminative stimulus effects of cocaine, reduced cocaine self-administration and blunted reinstatement of drug-seeking behavior after cocaine priming (Spealman and Bergman 1992, 1994; Glick et al. 1995; Negus et al. 1997; Mello and Negus 1998; Schenk et al. 1999) .
Previous work from our laboratory has shown that the kappa opioid agonists, at the doses evaluated in the present study, also reinstate cocaine seeking on their own (Valdez et al. 2007 ). Interestingly, unlike the effects observed in the present study, kappa opioid agonist-induced reinstatement could not be blocked by nor-BNI, only by relatively high doses of naltrexone. The priming effects of kappa opioid agonists also were attenuated by a corticotrophin-releasing factor antagonist as well as an alpha 2 -adrenoceptor agonist. These data raise the possibility that different subpopulations of kappa opioid receptors interact with different neurotransmitter systems to mediate the reinstatement-inducing vs. reinstatement-inhibiting effects of these ligands. The inhibitory effects of kappa opioid agonists with respect to the abuse-related effects of cocaine have frequently been attributed to their capacity to modulate the DA system. Kappa opioid agonists have been shown to inhibit DA release in the nucleus accumbens (Di Chiara and Imperato 1988; Spanagel et al. 1990; Thompson et al. 2000) , decrease striatal DA levels (Devine et al. 1993) , and inhibit firing of DA neurons (Walker et al. 1987) . However, several lines of evidence indicate that kappa opioid agonists also can alter the 5-HT system. For example, kappa opioid agonists have been found to enhance 5-HT release Takemori 1989, 1990; Berger et al. 2006 ) and induce behavioral effects that can be reversed by 5-HT depletion or with 5-HT antagonists (Von Voigtlander et al. 1984; Ho and Takemori 1989; Bronson et al. 1993; Powell et al. 1994) . In nonhuman primates, 5-HT appears to play a general inhibitory role in modulating the reinforcing and discriminative stimulus effects of cocaine (Spealman 1993; Howell and Byrd 1995; Czoty et al. 2002) . In the present study, high doses of the 5-HT transport inhibitors fluoxetine and citalopram also attenuated the priming effects of cocaine. These results support the idea that a common mechanism related to an increased concentration of 5-HT in the synapse, whether via kappa opioid agonist-induced release or blockade of the transporter by 5-HT transport inhibitors, may underlie the similar capacity of kappa opioid agonists and 5-HT transport inhibitors to attenuate the priming and other abuse-related effects of cocaine.
Our finding that pretreatment with high doses of 5-HT transport inhibitors attenuated cocaine priming-induced reinstatement in monkeys differs from results of a similar study in rats. Burmeister and colleagues (2003) showed that reinstatement of cocaine-seeking behavior induced by cocaine priming was unaltered following pretreatment with either fluoxetine or the 5-HT transport inhibitor/releaser d-fenfluramine, consistent with other studies showing that 5-HT transport inhibitors also fail to attenuate cocaine selfadministration and the discriminative stimulus effects of cocaine in rats, except at toxic doses (Cunningham and Callahan 1991; Tella 1995; Walsh and Cunningham 1997) . In another study in rats, however, cocaine priming-induced reinstatement was enhanced following depletion of brain 5-HT levels with the tryptophan hydroxylase inhibitor parachlorophenylalanine (Tran-Nguyen et al. 2001 ). This latter finding raises the possibility of an as yet to be determined role for 5-HT neurotransmission in cocaine priminginduced drug seeking in rats.
The reasons underlying the differences in monkey vs. rat studies is not clear. One possibility is the dose of the 5-HT transport inhibitor studied. As mentioned above, we evaluated only a single high dose of fluoxetine and citalopram. Another difference is the route by which the 5-HT transport inhibitor was administered (i.v. vs. i.p.) . Finally, there is the possibility of a species difference in the behavioral effects of 5-HT transport inhibitors reflecting neurogenetic and/or neuropharmacological differences in 5-HT systems in rodents compared to primates. For example, even though the coding sequences of monoamine transporters are relatively conserved across mammalian species, the greatest deviation in homology between rodents and primates was observed for the 5-HT transporter relative to the DA and norepinephrine transporter (Miller et al. 2001 ). In addition, using 5-HT uptake and radioligand binding assays, Barker and colleagues (1994) demonstrated that 5-HT transporter ligands can display differing potencies and efficacies at rodent compared to primate 5-HT transporters. These differences in the 5-HT system, as well as procedural differences, may form the basis for the It is perhaps not surprising that kappa opioid agonists are able to modulate 5-HT release. Anatomically, it has been shown that kappa opioid receptors are localized on serotonergic neurons in the ventral medulla (Kalyuzhny and Wessendorf 1999) and on terminals that release excitatory amino acids on serotonergic neurons in the dorsal raphé nucleus (Pinnock 1992) . To explore further the role of 5-HT in kappa agonist-induced attenuation of cocaine priming, we made use of the 5-HT 1A receptor agonist 8-OH-DPAT. 8-OH-DPAT decreases 5-HT release by preferentially activating 5-HT 1A autoreceptors (Hjorth and Magnusson 1988; Portas et al. 1996) . Thus, if kappa opioid agonists produced some of their cocaine-inhibiting effects by releasing 5-HT, 8-OH-DPAT should attenuate these effects. In the present study, results showed that spiradoline-as well as fluoxetine-induced inhibition of cocaine reinstatement was reversed by a relatively low, presumably autoreceptor-selective, dose of 8-OH-DPAT. The capacity of 8-OH-DPAT to antagonize both kappa opioid agonist-and 5-HT transport inhibitor-induced behavioral effects has been observed previously. For example, 8-OH-DPAT dose dependently attenuated the discriminative stimulus and rate-decreasing effects of U50,488H in pigeons trained to discriminate the kappa opioid agonist from vehicle (Bronson et al. 1993 ) and blocked conditioned nausea induced by fluoxetine in rats (Limebeer et al. 2009 ). Collectively, these results support the idea that modulation of 5-HT can be an important mechanism underlying the capacity of kappa opioid agonists to attenuate the abuse-related effects of cocaine.
A potential issue with the use of 8-OH-DPAT in combination with cocaine priming is previous findings showing that 8-OH-DPAT can enhance the reinforcing effects of low doses of cocaine in monkeys trained under a choice schedule (Czoty et al. 2005) and that 8-OH-DPAT can potentiate cocaine-induced hyperlocomotion in rats (Müller et al. 2003; Szumlinski et al. 2004) . These results raise the possibility that the increases in cocaine-seeking behavior observed when 8-OH-DPAT was given as a pretreatment in the present study were due simply to behavioral stimulant effects. However, this does not appear to be the case. Pretreatment with our selected dose of 8-OH-DPAT did not alter the effects of either low or high priming doses of cocaine nor did it induce cocaine-seeking behavior on its own across the dose range tested.
In summary, our results show that relatively high doses of kappa opioid agonists can attenuate reinstatement of cocaine-seeking behavior in monkeys, as they have been shown to do in rats. This finding extends previous work in monkeys demonstrating that kappa opioid agonists can attenuate other abuse-related effects of cocaine, including the reinforcing and discriminative stimulus effects. The kappa opioid agonist-induced inhibition of drug seeking was similar to the inhibition of drug seeking induced by relatively high doses of 5-HT transport inhibitors, indicating that increasing synaptic 5-HT is sufficient to blunt the priming effects of cocaine. Finally, the inhibitory effects of both kappa opioid agonists and 5-HT transport inhibitors could be reversed with a selected dose of 8-OH-DPAT, a 5-HT 1A agonist that has been shown to decrease 5-HT release. Taken together, our findings provide support for the idea that kappa opioid agonist-induced 5-HT release may at least partially underlie the capacity of these drugs to modulate the characteristic abuse-related effects of cocaine.
